DuPont will pay a fine of $1.275M to settle a federal complaint over eight chemical releases from a Kanawha County production facility, one of which killed a worker. The Department of Justice and U.S. Environmental Protection Agency said the settlement announced in a statement Wednesday resolves several alleged violations of federal law.
Moberg Pharma AB today announced that its head of U.S. operations, Steve Cagle, has announced...
That’s Nice LLC, a research-focused strategic marketing agency dedicated to life science markets...
Pharmaceutical Product Development, LLC (PPD) today announced the appointment of Robert Hureau...
Biogen Idec announced that Donald R. Johns, M.D., has joined the company as vice president, leading Biogen Idec’s amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub).
Eli Lilly and Co. says it will close its Elanco animal enzyme plant in Terre Haute by early 2016 as part of a consolidation push. Lilly spokesman Ed Sagebiel tells the Tribune-Star the Indianapolis-based company is consolidating all of its animal enzyme manufacturing to a site in Great Britain.
GE Healthcare Life Sciences today announced the appointment of Olivier Loeillot as General Manager, Asia Commercial for BioProcess. In this newly-created role Olivier will oversee commercial activities in the fast-moving Asian market for GE Healthcare Life Science’s rapidly growing BioProcess business.
Bioprocess Technology Consultants, Inc. (BPTC), a technical, and regulatory consulting company for the global biopharmaceutical industry, has promoted Susan Dana Jones, Ph.D., and Thomas C. Ransohoff to Principal Consultants.
Astellas has appointed Moyra Knight as the head of corporate and employee communications in the Americas region. Knight will report directly to Jeff Winton, senior vice president, chief communications officer.
Dendreon Corporation announced that its board of directors has appointed W. Thomas Amick as president and chief executive officer, effective immediately. Mr. Amick has also been appointed to the company’s board of directors.
Amgen said it will lay off 12 to 15 percent of its worldwide workforce and close four sites, even as it reported stellar second-quarter results that trounced Wall Street expectations.
ISPE has hired John Bournas as President and CEO, succeeding Nancy Berg who announced plans to leave the Society last fall. Mr. Bournas takes the helm at ISPE with extensive competencies in the healthcare association industry as well as significant international experience.
Allergan, Inc. announced operating results for the quarter ended June 30, 2014 and announced a restructuring that will eliminate 1500 jobs.
Aptuit Names Executive VP, Business Development & Marketing; Enhances Sterile Drug Product CapabilitiesJuly 16, 2014 11:33 am | News | Comments
Aptuit LLC has appointed Paul D. Overton, Ph.D., as Executive Vice President, Business Development and Marketing, making him responsible for all of Aptuit’s sales and marketing activities.
Bayer today announced the appointment of Malini Moorthy as Head of the Litigation Department in the United States, effective July 30. She succeeds Kaspar Stoffelmayr, whose three-year assignment ended and has rejoined Bartlit Beck Herman Palenchar & Scott LLP.
Repligen Corporation today announced that Jon K. Snodgres has been named its Chief Financial Officer. Mr. Snodgres joins Repligen from his CFO role at Maquet Cardiovascular, a medical device company.
Merck KGaA’s biopharmaceutical division today announced the appointment of Luciano Rossetti, M.D., as Executive Vice President and Global Head of Research & Development as of July 21, 2014.
Chinese authorities formally indicted two corporate investigators, an American and Briton, for allegedly illegally obtaining and selling private information, state media reported Monday. Prosecutors in Shanghai filed charges against British investigator Peter Humphrey and his wife Yingzeng Yu, a U.S. citizen, at the city's No. 1 Intermediate People's Court, the official Xinhua News Agency said.
ScinoPharm announced that after 17 years of dedicated service, its co-founder and President & CEO Dr. Jo Shen is retiring at the end of July 2014 and will be succeeded by Dr. Yung-Fa (Fred) Chen, currently Sr. Vice President of R&D and Chief Technology Officer, effective August 1, 2014.
Vertex Pharmaceuticals Incorporated today announced that Peter Mueller, Ph.D., Executive Vice President of Global Research and Development and Chief Scientific Officer, will retire after more than 10 years with the company.
Arena Pharmaceuticals, reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for BELVIQ by 50% to approximately 600.
Ortho-Clinical Diagnostics Announces Executive Leadership Additions as It Becomes an Independent, Stand-Alone CompanyJuly 8, 2014 8:58 am | News | Comments
Ortho-Clinical Diagnostics, Inc. unveiled its newly expanded executive leadership team following the acquisition of the company by The Carlyle Group from Johnson & Johnson.
AAIPharma Services Corp., a global provider of pharmaceutical analytical testing, product development and manufacturing services, and Cambridge Major Laboratories, Inc., a provider pharmaceutical API development and manufacturingservices, announced the appointment of Stephan Kutzer, Ph.D. as Chief Executive Officer (CEO), effective August 1, 2014.
Actavis has completed its $28 billion acquisition of fellow drugmaker Forest Laboratories, and the leader of the acquired company is now the CEO of Actavis.
Alexza Pharmaceuticals has announced the promotion of Edwin S. Kamemoto, Ph.D., to the newly created position of Senior Vice President, Regulatory Affairs. Dr. Kamemoto will have primary responsibility for leading and directing all regulatory affairs and global pharmacovigilence activities.
Seeking to turn around a troubled agency, President Barack Obama will nominate former Procter & Gamble executive Robert McDonald to lead a Veterans Affairs department gripped by reports of treatment delays and cover-ups.
Tris Pharma, a specialty pharmaceutical company focused on developing innovative technology-based products announced two key additions to its' executive team: Sally A. Berry, MD, PhD will join as Chief Medical Officer and Norma Cappetti will join as Vice President of Regulatory Affairs.
As a result of an in-depth review of the company’s research & development portfolio, InVivo Therapeutics has announced that the company is realigning resources behind its novel Neuro-Spinal Scaffold and the Neuro-Spinal Scaffold Plus Stem Cells program for spinal cord injury (SCI).
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Barry Lederman to the position of Vice President and Chief Financial Officer (CFO). In this role, Mr.Lederman will have full oversight and responsibility for leading Eisai's financial operations in the Americas Region.
- Page 1